BTS
CASC

BB&T Securities’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BB&T Securities’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-48,999
Closed -$181K – 1587
2017
Q4 		$181K Sell
48,999
-833
-2% -$3.41K ﹤0.01% 1366
2017
Q3 		$203K Buy
49,832
+11,118
+29% +$42.5K ﹤0.01% 1294
2017
Q2 		$143K Buy
+38,714
New +$154K ﹤0.01% 1327

BB&T Securities's CASC Position: Q1 2018 in Review

BB&T Securities sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 48,999 shares — an estimated $181K sold.

BB&T Securities first reported a position in CASC in Q2 2017 and held it in 3 quarters. The position peaked at $203K in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • BB&T Securities reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • BB&T Securities sold 48,999 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $181K.
  • BB&T Securities first reported a position in Cascadian Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • BB&T Securities's Cascadian Therapeutics, Inc. position peaked at $203K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on BB&T Securities's 13F filing for Q1 2018, filed 14 May 2018.